Drug Trial Radar · NCT01595438
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
598
Actual
Start
Oct 2012
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- May 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
Conditions
- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI)Drug
Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
DoripenemDrug
500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)Drug
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)Drug
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.
- Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
- Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
Locations
80 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Sylmar, California
Research Site
Royal Oak, Michigan
Research Site
Lima, Ohio
Research Site
Córdoba, Argentina
Research Site
Corrientes, Argentina
Research Site
Mendoza, Argentina
Research Site
Santa Fe, Argentina
Research Site
Belo Horizonte, Brazil
Research Site
Campinas/SP, Brazil
Research Site
Salvador, Brazil
Research Site
São José Do Rio Preto - SP, Brazil
Research Site
São Paulo, Brazil
Research Site
Vila Clementino, Brazil
Research Site
Pleven, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Zagreb, Croatia
Research Site
Kyjov, Czechia
Research Site
Opava, Czechia
Research Site
Jena, Germany
Research Site
Wuppertal, Germany
Research Site
Athens, Greece
Research Site
Budapest, Hungary
Research Site
Nagykanizsa, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Jerusalem, Israel
Research Site
Petah Tikva, Israel
Research Site
Safed, Israel
Research Site
Fukuoka, Japan
Research Site
Koshigaya-shi, Japan
Research Site
Kyoto, Japan
Research Site
Nagoya, Japan
Research Site
Nara, Japan
Research Site
Ōita, Japan
Research Site
Sendai, Japan
Research Site
Sunto-gun, Japan
Research Site
Tokushima, Japan
Research Site
Ueda-shi, Japan
Research Site
Utsunomiya, Japan
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.